

Date: 14th November, 2025

To,
Corporate Relations Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Company Code: ACCPL

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting dated 14th November, 2025
Reference: Disclosure pursuant to Regulations 30 read with Schedule III and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

With reference to the captioned subject, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. 14th November, 2025, has considered and approved Unaudited Financial Results for the half year ended 30th September, 2025 along with Limited Review Report of the Statutory Auditors thereon. The said Financial Results are enclosed herewith and will be available at Company's website www.accretionpharma.com.

The Board Meeting commenced at 03:00 p.m. and concluded at 04:25 p.m.

You are requested to kindly take on your record.

Thanking You.

Yours truly,
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary and Compliance Officer

Limited Review Report


To,
Board of Directors
ACCRETION PHARMACEUTICALS LIMITED
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi,
Ahmedabad,
Sanand -382213.

1. We have reviewed the accompanying statement of unaudited financial results of **ACCRETION PHARMACEUTICALS LIMITED** (CIN: L21004GJ2023PLC146545) for the half year ended 30th September, 2025 which are included in the accompanying "Statement of Unaudited Financial Result for half year ended September 30, 2025" together with relevant notes thereon. The statement has been prepared by company pursuant to regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The statement is the responsibility of the company's management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the AS 25 "Interim Financial Reporting (AS 25), prescribed under section 133 of the companies act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the ICAI. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an Audit. Accordingly, we do not express an Audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards ('AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


Date : 14/11/2025
Place : Ahmedabad



For, **V S S B & Associates**
Chartered Accountants.
Firm No. 121356W


(Vishves A. Shah)
Partner
M. No. 109944

UDIN: 25109944BMGQCTJ338

ACCRETION PHARMACEUTICALS LIMITED (CIN: L21004GJ2023PLC146545)					
Regd. Office :- 29 Xcelon Ind Park 1, B/h. Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213					
Unaudited Statement of Standalone Financial Result for the half year ended 30th September 2025					
	Particulars	Half Year Ended			(Amount in Lakhs)
		30-09-2025	30-09-2024	31-03-2025	Year Ended
		(Unaudited)	(Unaudited)	(Unaudited)	31-03-2025 (Audited)
I	Revenue from Operations	4373.62	1856.42	3881.20	5737.62
II	Other Income	11.05	1.53	7.91	9.44
III	Total Income (I + II)	4384.67	1857.95	3889.11	5747.06
IV	Expenses				
	Cost of Material Consumed	3439.68	1449.10	2921.91	4371.01
	Purchases	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(224.25)	(250.98)	(129.06)	(380.04)
	Employee Benefits Expenses	205.67	154.00	213.49	367.49
	Finance Costs	37.07	69.42	74.27	143.69
	Depreciation and Amortization Expense	39.97	36.70	40.75	77.45
	Other Expenses	245.45	70.35	120.73	191.08
	Total Expense	3743.59	1528.59	3242.09	4770.68
V	Profit before Exceptional and Extraordinary Items and Tax (III-IV)	641.07	329.36	647.02	976.38
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit before Extraordinary Items and Tax (V-VI)	641.07	329.36	647.02	976.38
VIII	Extraordinary Items	0.00	0.00	0.00	0.00
IX	Profit Before Tax (VII-VIII)	641.07	329.36	647.02	976.38
X	Tax Expense:				
	(a) Current Tax	161.35	82.89	177.04	259.93
	(b) Deferred Tax	4.51	0.00	19.32	19.32
	(c) MAT Credit Entitlement	0.00	0.00	0.00	0.00
	(d) Income Tax of Previous Year	0.00	0.00	17.78	17.78
	Total Tax Expense	165.85	82.89	214.14	297.03
XI	Profit for the Period from Continuing Operations (IX - X)	475.22	246.47	432.89	679.35
XII	Profit/(Loss) for the Period from Discontinuing Operations	0.00	0.00	0.00	0.00
XIII	Tax Expense of Discontinuing Operations	0.00	0.00	0.00	0.00
XIV	Profit/(Loss) from Discontinuing Operations (After Tax) (XII-XIII)	0.00	0.00	0.00	0.00
XV	Profit for the Period (XI + XIV)	475.22	246.47	432.89	679.35
XVI	Paid up Share Capital (Face Value Rs. 10/Share)	1111.60	817.00	817.00	817.00
XVII	Reserve excluding Revaluation Reserves	0.00	0.00	0.00	711.65
XVIII	Earnings Per Equity Share:				
	Basic (Rs.) & Diluted	4.61	3.14	5.30	8.48
Notes: 1 The above Un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th November 2025. 2 The previous periods figures have been regrouped wherever necessary. 3 The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made. 4 The company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025. 5 Earning per share is not retrospectively effected due to Fresh issue of equity as it is considered as Non-Adjusting event as per AS 4 'Contingencies and Events Occurring After the Balance Sheet Date'. 6 Statement on Utilisation of proceeds from the preferential issue of the Equity Shares is attached herewith as additional disclosure.					
Place: Ahmedabad Date : 14/11/2025		For and on Behalf of the Board of, ACCRETION PHARMACEUTICALS LIMITED  Vivek Ashok Kumar Patel (Managing Director) DIN : 09130357			

ACCRETION PHARMACEUTICALS LIMITED

(CIN: L21004GJ2023PLCT46545)

Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Unaudited Statement of Assets & Liabilities as at 30th September, 2025



		(Amount in Lakhs)	
	Particulars	Unaudited AS AT 30-09-2025	Audited AS AT 31-03-2025
I	Equity & Liabilities		
	1. Shareholders' funds		
	(a) Share Capital	1111.60	817.00
	(b) Reserves and Surplus	3546.26	711.65
	(c) Money received against share warrants	0.00	0.00
	2. Share application money pending allotment	0.00	0.00
	Total	4657.86	1528.65
	3. Non - Current Liabilities		
	(a) Long -Term Borrowings	74.47	116.76
	(b) Deferred Tax Liabilities (Net)	23.96	19.45
	(c) Other Long - Term Liabilities	0.00	0.00
	(d) Long - Term Provisions	0.00	0.00
	4. Current Liabilities		
	(a) Short - Term Borrowings	711.09	1293.58
	(b) Trade Payables		
	Micro and Small Enterprises	226.32	183.90
	Other than Micro and Small Enterprises	41.06	574.72
	(c) Other Current Liabilities	4.38	4.47
	(d) Short - Term Provisions	168.33	265.90
	Total	1249.61	2458.79
	Total	5907.47	3987.44
II	Assets		
	1. Non - Current Assets		
	(a) Property, Plant & Equipment & Intangible Assets		
	(i) Property, Plant & Equipment	866.66	609.09
	(ii) Intangible Assets	0.00	0.00
	(iii) Capital Work-in-Progress	0.00	0.00
	(iv) Intangible Assets under Development	0.00	0.00
	(b) Non - Current Investments	0.00	0.00
	(c) Long - Term Loans and Advances	12.10	7.56
	(d) Other Non - Current Assets	24.03	16.08
	(d) Deferred Tax Assets (Net)	0.00	0.00
		902.79	632.73
	2. Current Assets		
	(a) Inventories	2283.46	2060.97
	(b) Trade Receivables	2184.82	1166.11
	(c) Cash and Cash equivalents	15.58	5.08
	(d) Short - Term Loans and Advances	231.39	110.36
	(e) Other Current Assets	289.42	12.18
		5004.68	3354.71
	Total	5907.47	3987.44

Place : Ahmedabad
Date : 14/11/2025

For & on behalf of the Board,
ACCRETION PHARMACEUTICALS LIMITED



[Signature]
Vivek Ashok Kumar Patel
(Managing Director)
DIN : 09130357

ACCRETION PHARMACEUTICALS LIMITED				
(CIN: L21004GJ2023PLC146545)				
Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213				
UNAUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th September 2025				
(Amount in Lakhs)				
Particulars	Period ended 30th September, 2025 (Unaudited) Rs.		Year ended 31st March, 2025 (Audited) Rs.	
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit before Tax for the year		641.07		976.38
Adjustments for :				
Transferred from reserve	0.00		0.00	
Interest Expense	37.07		143.69	
Depreciation	39.97		77.45	
		77.04		221.14
Operating Profit before Working Capital change		718.12		1197.53
Adjustments for :				
Decrease/(Increase) in Receivables	(1018.71)		(585.67)	
Decrease/(Increase) in Inventories	(222.49)		(613.38)	
Decrease/(Increase) in Other Current Assets	(277.24)		(6.73)	
Increase/(Decrease) in Payables	(491.24)		100.87	
Increase/(Decrease) in Current Liabilities	(0.09)		1.47	
Other Non Current Asset	(7.95)		(2.70)	
Increase/(Decrease) in Provisions	(97.58)	(2115.30)	45.01	(1061.13)
Cash Generated From Operations		(1397.18)		136.39
Income Tax		161.35		185.77
NET CASH FROM OPERATING ACTIVITIES Total (A)		(1558.53)		(49.37)
CASH FLOW FROM INVESTING ACTIVITIES				
Non Current Investment	0.00		0.00	
Purchase Of Fixed Asset	(297.54)		(161.08)	
Loans & Advances Given	(125.57)		(12.51)	
NET CASH USED IN INVESTING ACTIVITIES Total (B)		(423.11)		(173.58)
CASH FLOW FROM FINANCING ACTIVITIES				
Net Repayment of Borrowing	(624.78)		0.00	
Proceeds from share issued (net off share issuing expense)	2654.00		300.00	
Net Proceeds from Borrowing	0.00		62.57	
Interest Expenses	(37.07)		(143.69)	
NET CASH FROM FINANCING ACTIVITIES Total (C)		1992.14		218.87
Net Increase/(Decrease) in Cash and Cash Equivalents Total (A+B+C)		10.51		(4.08)
Cash and Cash Equivalents - Opening Balance		5.08		9.16
Cash and Cash Equivalents - Closing Balance		15.58		5.08
		(0.00)		0.00
Note: Previous year's figures have been regrouped/rearranged wherever considered necessary.				
<p style="text-align: right;">For & on behalf of the Board, ACCRETION PHARMACEUTICALS LIMITED</p> <div style="display: flex; justify-content: space-between; align-items: center;"> <div> <p>Place : Ahmedabad Date : 14/11/2025</p> </div> <div style="text-align: center;">  </div> <div> <p style="text-align: right;">  Vivek Ashok Kumar Patel (Managing Director) DIN : 09130357 </p> </div> </div>				

Additional Disclosure			
Statement on Utilisation of proceeds from the Initial Public Offer of the Equity Shares: -			
Pursuant to the issue of Fresh Equity Shares, the Company has received proceeds from the Initial Public Offer of the Equity Shares from the allottees. The utilisation of such funds as of 30th September 2025 is detailed below:			
Object as stated in Prospectus	Projected Utilisation in the offer document	Actual utilisation of fund till 30-09-2025	Balance amount to be utilised
Total proceeds from the Initial public offer of the Equity Shares	2,975.46		
Utilised for:			
Capital Expenditure towards purchase of new equipment / machineries, etc*	269.73	269.73	-
Capital Expenditure towards upgradation of existing manufacturing facility	465.57	374.81	90.76
Repayment / Prepayment of certain borrowings availed by our company**	99.17	99.17	-
Funding working capital requirements	1,468.00	1,358.76	109.24
General Corporate Purpose	442.97	442.97	-
IPO Related Expense	230.02	230.02	-
Total	2,975.46	2,775.46	
Unutilised Balance			200.00
<p>Note: The balance amount, if any, remains invested in short-term fixed deposits or bank balances, pending deployment for approved purposes.</p> <p>Note:</p> <p>1. *Capital Expenditure towards purchase of new equipment / machineries, etc: The Company has utilized the funds for the purchase of new equipment and machinery in accordance with the disclosures made in its Prospectus. Furthermore, an additional amount of ₹1.29 lakhs has been utilized from the Company's internal accruals/own funds.</p> <p>2. ** Repayment / Prepayment of certain borrowings availed by our company: During the period of Listing: an installment of the borrowings has been due for the payment, and the company has paid the said due installment from its own fund and after the listing proceedings received, company has paid off the remaining amount of the borrowings, as stated in the object of the Initial public offer.</p> <p>Note : The Company confirms that the utilisation is in accordance with the objects stated in the offer documents/resolutions passed for the issue of Equity Shares. Utilisation has been reviewed by the Audit Committee.</p>			

